Antibody-guided vaccine design: Identification of protective epitopes

Current Opinion in Immunology

Volumn 41, Issue , 2016, Pages 62-67

  Lanzavecchia, Antonio ^a,b   Frühwirth, Alexander ^a   Perez, Laurent ^a   Corti, Davide ^c  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c Humabs BioMed ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MALARIA VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RECOMBINANT PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VACCINE; VARIANT SURFACE GLYCOPROTEIN; VIRUS ENVELOPE PROTEIN; ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; CYTOMEGALOVIRUS INFECTION; DRUG DESIGN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; INFLUENZA A; MEMORY CELL; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN ENGINEERING; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; VIRUS NEUTRALIZATION; ANIMAL; IMMUNOLOGY; VACCINATION;

ANIMALS; ANTIBODIES; EPITOPES; HUMANS; VACCINATION; VACCINES;

EID: 84975252055     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.06.001     Document Type: Review

References (61)

1. Pinna D., Corti D., Jarrossay D., Sallusto F., Lanzavecchia A. Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur J Immunol 2009, 39:1260-1270.
2. Corti D., Langedijk J.P.M., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., Silacci C., Pinna D., Jarrossay D., Balla-Jhagjhoorsingh S., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010, 5:e8805.
3. Pötzsch S., Spindler N., Wiegers A-K., Fisch T., Rücker P., Sticht H., Grieb N., Baroti T., Weisel F., Stamminger T., et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 2011, 7:e1002172.
4. Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007, 17:253-276.
5. Compton T. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol 2004, 14:5-8.
6. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.-L., Corey L., Hill J., Davis E., Flanigan C., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360:1191-1199.
7. Macagno A., Bernasconi N.L., Vanzetta F., Dander E., Sarasini A., Revello M.G., Gerna G., Sallusto F., Lanzavecchia A. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010, 84:1005-1013.
8. Wang D., Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A 2005, 102:18153-18158.
9. Loughney J.W., Rustandi R.R., Wang D., Troutman M.C., Dick L.W., Li G., Liu Z., Li F., Freed D.C., Price C.E., et al. Soluble human cytomegalovirus gH/gL/pUL128-131 pentameric complex, but not gH/gL, inhibits viral entry to epithelial cells and presents dominant native neutralizing epitopes. J Biol Chem 2015, 290:15985-15995.
10. Kabanova A., Perez L., Lilleri D., Marcandalli J., Agatic G., Becattini S., Preite S., Fuschillo D., Percivalle E., Sallusto F., et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A 2014, 111:17965-17970.
11. Hofmann I., Wen Y., Ciferri C., Schulze A., Fühner V., Leong M., Gerber A., Gerrein R., Nandi A., Lilja A.E., et al. Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system. Biotechnol Bioeng 2015, 112:2505-2515.
12. Barfod L., Bernasconi N.L., Dahlbäck M., Jarrossay D., Andersen P.H., Salanti A., Ofori M.F., Turner L., Resende M., Nielsen M.A., et al. Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA. Mol Microbiol 2006, 63:335-347.
13. Tan J., Pieper K., Piccoli L., Abdi A., Foglierini M., Geiger R., Maria Tully C., Tully C.M., Jarrossay D., Ndungu F.M., et al. A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens. Nature 2015, 529:105-109.
14. Robbiani D.F., Nussenzweig R.S. A new way to diversify antibodies by DNA transposition. Cell 2016, 164:601-602.
15. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
16. McLellan J.S., Yang Y., Graham B.S., Kwong P.D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 2011, 85:7788-7796.
17. Swanson K.A., Settembre E.C., Shaw C.A., Dey A.K., Rappuoli R., Mandl C.W., Dormitzer P.R., Carfi A. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 2011, 108:9619-9624.
18. Smith G., Raghunandan R., Wu Y., Liu Y., Massare M., Nathan M., Zhou B., Lu H., Boddapati S., Li J., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS ONE 2012, 7:e50852.
19. Correia B.E., Bates J.T., Loomis R.J., Baneyx G., Carrico C., Jardine J.G., Rupert P., Correnti C., Kalyuzhniy O., Vittal V., et al. Proof of principle for epitope-focused vaccine design. Nature 2014, 507:201-206.
20. Schickli J.H., Whitacre D.C., Tang R.S., Kaur J., Lawlor H., Peters C.J., Jones J.E., Peterson D.L., McCarthy M.P., Van Nest G., et al. Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J Clin Invest 2015, 125:1637-1647.
21. Magro M., Mas V., Chappell K., Vázquez M., Cano O., Luque D., Terrón M.C., Melero J.A., Palomo C. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A 2012, 109:3089-3094.
22. Ngwuta J.O., Chen M., Modjarrad K., Joyce M.G., Kanekiyo M., Kumar A., Yassine H.M., Moin S.M., Killikelly A.M., Chuang G.-Y., et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 2015, 7. 309ra162-309ra162.
23. Corti D., Bianchi S., Vanzetta F., Minola A., Perez L., Agatic G., Guarino B., Silacci C., Marcandalli J., Marsland B.J., et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 2013, 501:439-443.
24. Kwakkenbos M.J., Diehl S.A., Yasuda E., Bakker A.Q., van Geelen C.M.M., Lukens M.V., van Bleek G.M., Widjojoatmodjo M.N., Bogers W.M.J.M., Mei H., et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 2009, 16:123-128.
25. McLellan J.S., Chen M., Leung S., Graepel K.W., Du X., Yang Y., Zhou T., Baxa U., Yasuda E., Beaumont T., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013, 340:1113-1117.
26. McLellan J.S., Chen M., Joyce M.G., Sastry M., Stewart-Jones G.B.E., Yang Y., Zhang B., Chen L., Srivatsan S., Zheng A., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013, 342:592-598.
27. Stewart-Jones G.B.E., Thomas P.V., Chen M., Druz A., Joyce M.G., Kong W.-P., Sastry M., Soto C., Yang Y., Zhang B., et al. A cysteine zipper stabilizes a pre-fusion F glycoprotein vaccine for respiratory syncytial virus. PLOS ONE 2015, 10:e0128779.
28. Corti D., Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 2013, 31:705-742.
29. Burton D.R., Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol 2016, 34:635-659.
30. Schmidt A.G., Therkelsen M.D., Stewart S., Kepler T.B., Liao H.-X., Moody M.A., Haynes B.F., Harrison S.C. Viral receptor-binding site antibodies with diverse germline origins. Cell 2015, 161:1-18.
31. Throsby M., van den Brink E., Jongeneelen M., Poon L.L.M., Alard P., Cornelissen L., Bakker A., Cox F., van Deventer E., Guan Y., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 2008, 3:e3942-e4015.
32. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.-M., Santelli E., Stec B., Cadwell G., Ali M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
33. Corti D., Suguitan A.L., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F., Santos C., Luke C.J., Torres-Velez F.J., Temperton N.J., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010, 120:1663-1673.
34. Wrammert J., Koutsonanos D., Li G.-M., Edupuganti S., Sui J., Morrissey M., McCausland M., Skountzou I., Hornig M., Lipkin W.I., et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011, 208:181-193.
35. Ekiert D.C., Friesen R.H.E., Bhabha G., Kwaks T., Jongeneelen M., Yu W., Ophorst C., Cox F., Korse H.J.W.M., Brandenburg B., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333:843-850.
36. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., Vachieri S.G., Pinna D., Minola A., Vanzetta F., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856.
37. Dreyfus C., Laursen N.S., Kwaks T., Zuijdgeest D., Khayat R., Ekiert D.C., Lee J.H., Metlagel Z., Bujny M.V., Jongeneelen M., et al. Highly conserved protective epitopes on influenza B viruses. Science 2012, 337:1343-1348.
38. Nakamura G., Chai N., Park S., Chiang N., Lin Z., Chiu H., Fong R., Yan D., Kim J., Zhang J., et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 2013, 14:93-103.
39. Pappas L., Foglierini M., Piccoli L., Kallewaard N.L., Turrini F., Silacci C., Fernandez-Rodriguez B., Agatic G., Giacchetto-Sasselli I., Pellicciotta G., et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 2014, 516:418-422.
40. Yewdell J.W. To dream the impossible dream: universal influenza vaccination. Curr Opin Virol 2013, 3:316-321.
41. Hai R., Krammer F., Tan G.S., Pica N., Eggink D., Maamary J., Margine I., Albrecht R.A., Palese P. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 2012, 86:5774-5781.
42. Krammer F., Palese P. Universal influenza virus vaccines: need for clinical trials. Nat Immunol 2014, 15:3-5.
43. Steel J., Lowen A.C., Wang T.T., Yondola M., Gao Q., Haye K., García-Sastre A., Palese P. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010, 1. e00018-10.
44. Yassine H.M., Boyington J.C., McTamney P.M., Wei C.-J., Kanekiyo M., Kong W.-P., Gallagher J.R., Wang L., Zhang Y., Joyce M.G., et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 2015, 21:1065-1070.
45. López-Sagaseta J., Malito E., Rappuoli R., Bottomley M.J. Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J 2016, 14:58-68.
46. King N.P., Bale J.B., Sheffler W., McNamara D.E., Gonen S., Gonen T., Yeates T.O., Baker D. Accurate design of co-assembling multi-component protein nanomaterials. Nature 2014, 510:103-108.
47. Impagliazzo A., Milder F., Kuipers H., Wagner M.V., Zhu X., Hoffman R.M.B., van Meersbergen R., Huizingh J., Wanningen P., Verspuij J., et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015, 349:1301-1306.
48. DiLillo D.J., Tan G.S., Palese P., Ravetch J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 2014, 20:143-151.
49. DiLillo D.J., Palese P., Wilson P.C., Ravetch J.V. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 2016, 126:605-610.
50. Victora G.D., Nussenzweig R.S. Germinal centers. Annu Rev Immunol 2012, 30:429-457.
51. Andrews S.F., Huang Y., Kaur K., Popova L.I., Ho I.Y., Pauli N.T., Henry Dunand C.J., Taylor W.M., Lim S., Huang M., et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med 2015, 7. 316ra192-316ra192.
52. Andrews S.F., Kaur K., Pauli N.T., Huang M., Huang Y., Wilson P.C. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response. J Virol 2015, 89:3308-3317.
53. Huang K.-Y.A., Rijal P., Schimanski L., Powell T.J., Lin T.-Y., McCauley J.W., Daniels R.S., Townsend A.R. Focused antibody response to influenza linked to antigenic drift. J Clin Invest 2015, 125:2631-2645.
54. Wang S., Mata-Fink J., Kriegsman B., Hanson M., Irvine D.J., Eisen H.N., Burton D.R., Wittrup K.D., Kardar M., Chakraborty A.K. Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. Cell 2015, 160:785-797.
55. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
56. Ippolito G.C., Beausang J., Busse C.E., Wardemann H., Quake S.R., Georgiou G. The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat Biotechnol 2014, 32:158-168.
57. Liao H.-X., Lynch R., Zhou T., Gao F., MunirAlam S., Boyd S.D., Fire A.Z., Roskin K.M., Schramm C.A., Zhang Z., et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013, 496:469-476.
58. Julien J.P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
59. Lyumkis D., Julien J.P., de Val N., Cupo A., Potter C.S., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., Carragher B., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
60. Pancera M., Zhou T., Druz A., Georgiev I.S., Soto C., Gorman J., Huang J., Acharya P., Chuang G.-Y., Ofek G., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514:1-24.
61. Haynes B.F., Kelsoe G., Harrison S.C., Kepler T.B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012, 30:423-433.